2,2-二氧代-1,3-二氢苯并[c]噻吩-5-胺 | 70654-85-2

• 分子结构分类: 有机化合物 - 苯类化合物
• 中文名称: 2,2-二氧代-1,3-二氢苯并[c]噻吩-5-胺
• 中文别名: 2-氧代-1,3-二氢-苯并[C]噻吩-5-氨基
• 英文名称: 5-amino-1,3-dihydrobenzo[c]thiophene 2,2-dioxide
• 英文别名: 2,2-dioxo-1,3-dihydro-2-benzothiophen-5-amine
• CAS: 70654-85-2
• 化学式: C₈H₉NO₂S
• mdl: MFCD00178261
• 分子量: 183.231
• InChiKey: HFUIQDXPKOCDLV-UHFFFAOYSA-N

物化性质

• 熔点：
  186 °C
• 沸点：
  483.4±45.0 °C(Predicted)
• 密度：
  1.438±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  68.5
• 氢给体数：
  1
• 氢受体数：
  3

SDS

Name:	2 2-Dioxo-1 3-dihydrobenzo[c]thiophene-5ylamine Material Safety Data Sheet
Synonym:
CAS:	70654-85-2

Section 1 - Chemical Product MSDS Name:2 2-Dioxo-1 3-dihydrobenzo[c]thiophene-5ylamine Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
70654-85-2	2,2-Dioxo-1,3-dihydrobenzo[c]thiophene	80+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes. Avoid ingestion and inhalation.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Keep under a nitrogen blanket.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 70654-85-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Off White
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 188 - 192 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H9NO2S
Molecular Weight: 183.23

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong acids, acid chlorides.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Not available.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 70654-85-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,2-Dioxo-1,3-dihydrobenzo[c]thiophene-5ylamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Other No information available.

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.*
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
IMO
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing Group: III
RID/ADR
Shipping Name: TOXIC SOLID, ORGANIC, N.O.S.
Hazard Class: 6.1
UN Number: 2811
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 70654-85-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 70654-85-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 70654-85-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,2-二氧代-1,3-二氢苯并[c]噻吩-5-胺 在 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 三氟乙酸 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 2-(2,6-difluorophenyl)-4-((2,2-dioxido-1,3-dihydrobenzo[c]thiophen-5-yl)amino)-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-5-one
  参考文献：
  名称：

  TYK2 INHIBITORS AND USES THEREOF

  摘要：

  本发明提供了化合物、其组合物以及使用这些化合物来抑制TYK2并治疗TYK2介导的疾病的方法。

  公开号：

  US20160251376A1
• 作为产物：
  描述：

  4-硝基邻二甲苯 在 N-溴代丁二酰亚胺(NBS) 、 四丁基溴化铵 、 甲酸铵 、 rongalite 、 锌 、 过氧化苯甲酰 作用下， 以 甲醇 、 四氯化碳 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 42.0h， 生成 2,2-二氧代-1,3-二氢苯并[c]噻吩-5-胺
  参考文献：
  名称：

  苯砜作为光化学活化的二氧化硫（SO 2）供体†

  摘要：

  二氧化硫（SO 2）是一种气态环境污染物，在工业上通常用作防腐剂和抗菌剂。最新数据表明，SO 2可能具有治疗作用。然而，由于其气态性质，本地化SO 2的产生是具有挑战性的。在此，制备各种1，3-二氢苯并[ c ]噻吩2，2-二氧化物（苯并砜）作为光化学活化的二氧化硫（SO 2）产生的候选物。发现这些化合物在缓冲液中稳定，但在紫外线照射下会被光解产生SO 2。。我们的数据表明苯砜的光解取决于取代基，并且给电子基团的存在导致SO 2的产率提高。

  DOI：

  10.1039/c4ob02466d
• 作为试剂：
  描述：

  四氢吡咯 、 1-chloro-8-(methyloxy)-9-(1-pyrrolidinylsulfonyl)-5,6-dihydrobenzo[f]quinazolin-3-amine 在 2,2-二氧代-1,3-二氢苯并[c]噻吩-5-胺 作用下， 以 异丙醇 为溶剂， 反应 0.25h， 生成 8-(methyloxy)-1-(1-pyrrolidinyl)-9-(1-pyrrolidinylsulfonyl)-5,6-dihydrobenzo[f]quinazolin-3-amine
  参考文献：
  名称：

  WO2008/86158

  摘要：

  公开号：

文献信息

• [EN] THIAZOLE AND OXAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE À BASE DE THIAZOLE ET D'OXAZOLE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009032667A1

  公开（公告）日：2009-03-12

  The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供噻唑和氧唑化合物，含有这些化合物的组合物，以及用作药用剂的制备方法和使用方法。
• 1,2,6-Thiadiazinones as Novel Narrow Spectrum Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CaMKK2) Inhibitors
  作者：Christopher Asquith、Paulo Godoi、Rafael Couñago、Tuomo Laitinen、John Scott、Christopher Langendorf、Jonathan Oakhill、David Drewry、William Zuercher、Panayiotis Koutentis、Timothy Willson、Andreas Kalogirou

  DOI：10.3390/molecules23051221

  日期：——

  demonstrate for the first time that 4H-1,2,6-thiadiazin-4-one (TDZ) can function as a chemotype for the design of ATP-competitive kinase inhibitors. Using insights from a co-crystal structure of a 3,5-bis(arylamino)-4H-1,2,6-thiadiazin-4-one bound to calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2), several analogues were identified with micromolar activity through targeted displacement of

  我们首次证明了4H-1,2,6-噻二嗪-4-酮（TDZ）可以用作设计ATP竞争性激酶抑制剂的化学型。利用结合到钙/钙调蛋白依赖性蛋白激酶2（CaMKK2）的3,5-双（芳基氨基）-4H-1,2,6-噻二嗪-4-酮的共晶体结构获得的见解，得到了几种类似物通过结合的水分子在活性位点的靶向置换而具有微摩尔活性。由于TDZ类似物与其2，4-二苯并嘧啶对立物相比显示出降低的滥交性，因此它们代表了开发高选择性激酶抑制剂的起点。
• Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors
  申请人：SmithKline Beecham Corporation

  公开号：US06369086B1

  公开（公告）日：2002-04-09

  The present invention relates generally to novel substituted oxindole compounds and compositions. Such compounds and compositions have utility as pharmacological agents in treating diseases or conditions alleviated by the inhibition or antagonism of protein kinase activated signalling pathways. In particular, the present invention relates to a series of substituted oxindole compounds, which exhibit protein tyrosine kinase and protein serine/threonine kinase inhibition, and which are useful in inhibiting tumor growth via inhibition of such kinases as well as protecting a patient undergoing chemotherapy from chemotherapy induced alopecia.

  本发明总体上涉及新颖的取代吲哚化合物和组合物。这类化合物和组合物作为治疗药物，在治疗通过抑制或拮抗蛋白激酶激活的信号通路而缓解的疾病或状况方面具有效用。特别是，本发明涉及一系列取代吲哚化合物，这些化合物表现出蛋白酪氨酸激酶和蛋白丝氨酸/苏氨酸激酶的抑制作用，并且可用于通过抑制这些激酶来抑制肿瘤生长，以及保护接受化疗的患者免受化疗引起的脱发。
• Optimization of 4-Anilinoquinolines as Dengue Virus Inhibitors
  作者：Pei-Tzu Huang、Sirle Saul、Shirit Einav、Christopher R. M. Asquith

  DOI：10.3390/molecules26237338

  日期：——

  Emerging viral infections, including those caused by dengue virus (DENV) and Venezuelan Equine Encephalitis virus (VEEV), pose a significant global health challenge. Here, we report the preparation and screening of a series of 4-anilinoquinoline libraries targeting DENV and VEEV. This effort generated a series of lead compounds, each occupying a distinct chemical space, including 3-((6-bromoquinolin-4-yl)amino)phenol (12), 6-bromo-N-(5-fluoro-1H-indazol-6-yl)quinolin-4-amine (50) and 6-((6-bromoquinolin-4-yl)amino)isoindolin-1-one (52), with EC50 values of 0.63–0.69 µM for DENV infection. These compound libraries demonstrated very limited toxicity with CC50 values greater than 10 µM in almost all cases. Additionally, the lead compounds were screened for activity against VEEV and demonstrated activity in the low single-digit micromolar range, with 50 and 52 demonstrating EC50s of 2.3 µM and 3.6 µM, respectively. The promising results presented here highlight the potential to further refine this series in order to develop a clinical compound against DENV, VEEV, and potentially other emerging viral threats.

  新兴病毒感染，包括那些由登革热病毒（DENV）和委内瑞拉马脑炎病毒（VEEV）引起的感染，构成了全球重大的健康挑战。在这里，我们报告了针对DENV和VEEV的一系列4-苯胺基喹啉类化合物库的制备和筛选工作。这一努力产生了一系列主导化合物，每个化合物占据着不同的化学空间，包括3-((6-溴喹啉-4-基)氨基)酚（12）、6-溴-N-(5-氟-1H-吲哚-6-基)喹啉-4-胺（50）和6-((6-溴喹啉-4-基)氨基)异吲哚啉-1-酮（52），对DENV感染的EC50值为0.63-0.69 µM。这些化合物库在几乎所有情况下表现出非常有限的毒性，CC50值大于10 µM。此外，主导化合物被筛选用于对抗VEEV，并在低个位数微摩尔范围内展示了活性，其中50和52的EC50分别为2.3 µM和3.6 µM。这里呈现的有希望的结果突显了进一步完善这一系列的潜力，以开发针对DENV、VEEV和潜在其他新兴病毒威胁的临床化合物。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2010019637A1

  公开（公告）日：2010-02-18

  The invention is directed to pyrido[4,3-d]pyrimidin-5(6H)-one derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1, R2, R3, and R4 are defined below. The compounds of the invention are inhibitors of PDK1 and can be useful in the treatment of disorders characterized by constitutively activated ACG kinases such as cancer and more specifically cancers of the breast, colon, and lung. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting PDK1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention

  这项发明涉及吡啶并[4,3-d]嘧啶-5(6H)-酮衍生物。具体而言，该发明涉及符合以下式(I)的化合物，其中R1、R2、R3和R4如下所定义。该发明的化合物是PDK1的抑制剂，可用于治疗由于ACG激酶持续活化而表现出的疾病，如癌症，尤其是乳腺癌、结肠癌和肺癌。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物来抑制PDK1活性和治疗相关疾病的方法。